Prostatic Neoplasms: Clinical Trials

304 trials for Prostatic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

304 completed. 304 Phase 3, 32 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3304Completed 304
Phase 232Completed 32

Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms

Trials (filtered) newest first · largest first

All 304 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
QLG1080 - Prostate Cancer
Phase 3CompletedQilu Pharmaceutical Co., Ltd.1112025-03-112026-09-03
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Florastamin[18F] Injection - Prostate Cancer
Phase 3CompletedHTA Co., Ltd.1312024-12-192026-09-25
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma
Phase 3CompletedCurium US LLC2352024-04-012026-02-18
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Copper Cu 64 PSMA I&T - Prostate Cancer, Prostate Adenocarcinoma
Phase 3CompletedCurium US LLC4432024-04-012026-11-19
Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
[18F]Florastamin Injection - Prostate Cancer
Phase 3CompletedHTA Co., Ltd.2872023-10-202026-09-29
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Relugolix, Leuprolide Acetate - Prostate Cancer
Phase 3CompletedSumitomo Pharma America, Inc.3872023-01-282026-06-15
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Triptorelin pamoate (embonate) salt - Advanced Prostate Cancer, Metastatic Prostate Cancer
Phase 3CompletedIpsen1952022-11-172025-09-09
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
Triptorelin embonate 22.5 mg - Prostate Cancer
Phase 3CompletedIpsen1472022-08-302025-07-25
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 3CompletedMayo Clinic1632022-05-092025-07-18
Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)
PSMA PET guided prostate biopsy, MRI directed TRUS guided prostate biopsy - Prostate Cancer, Prostate Neoplasm
Phase 2 / Phase 3CompletedPost Graduate Institute of Medical Education and Research, Chandigarh2172021-10-252025-08-07
Study of Diagnostic Performance of [18F]CTT1057 in BCR
[18F]CTT1057, [68Ga]Ga-PSMA-11 - Prostatic Neoplasms, Prostate Cancer
Phase 3CompletedNovartis Pharmaceuticals1902021-09-302025-10-20
68Ga-PSMA-11 PET in Patients With Prostate Cancer
Ga-PSMA-11 - Prostate Cancer, Prostate Adenocarcinoma
Phase 3CompletedUniversity of Colorado, Denver392021-09-292023-11-13
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
[18F]CTT1057 - Prostatic Neoplasms, Prostate Cancer
Phase 2 / Phase 3CompletedNovartis Pharmaceuticals1952021-09-072025-10-07
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
[18F]PSMA-1007 - Prostate Cancer, Prostate Cancer Recurrent
Phase 3CompletedABX advanced biochemical compounds GmbH1362021-08-272025-07-15
Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy
Sugammadex 6 mg/kg, Sugammadex 4 mg/kg - Prostate Cancer, Neuromuscular Blockade
Phase 3CompletedFondazione Policlinico Universitario Agostino Gemelli IRCCS342021-07-132023-01-25
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT - Prostatic Neoplasms
Phase 3CompletedNovartis Pharmaceuticals4692021-06-152026-11-04
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
TAVT-45, Zytiga, Prednisone - Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Phase 3CompletedTavanta Therapeutics1072021-05-052024-01-16
Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT
Sodium Fluoride F-18 Injection, Technetium[99mTc] Methylenediphosphonate Injection - Bone Metastases
Phase 3CompletedHTA Co., Ltd.2802021-03-292022-11-14
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
Rucaparib - Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
Phase 3Completedpharmaand GmbH342021-03-222024-05-07
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Darolutamide (Nubeqa, BAY1841788), Placebo, Androgen deprivation therapy (ADT) - Prostatic Neoplasms
Phase 3CompletedBayer6692021-02-232026-09-29

Showing 20 of 304. Sign in to see all of them.

Narrower conditions

Neoplasms (21)  ·  Neoplasm Metastasis (16)  ·  Breast Neoplasms (14)  ·  Pain (10)  ·  Osteoporosis (6)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Disease (5)  ·  Lung Neoplasms (5)  ·  Colonic Neoplasms (4)  ·  Multiple Myeloma (4)  ·  Ovarian Neoplasms (4)  ·  Prostatic Neoplasms, Castration-Resistant (4)  ·  Rectal Neoplasms (4)  ·  Uterine Cervical Neoplasms (4)

Broader conditions

Genital Diseases (304)  ·  Urogenital Diseases (304)  ·  Genital Diseases, Male (302)  ·  Male Urogenital Diseases (302)  ·  Neoplasms by Site (302)  ·  Prostatic Diseases (302)  ·  Urogenital Neoplasms (302)  ·  Genital Neoplasms, Male (301)  ·  Neoplasms (283)  ·  Pathological Conditions, Signs and Symptoms (40)  ·  Pathologic Processes (27)  ·  Neoplastic Processes (17)  ·  Signs and Symptoms (17)  ·  Breast Diseases (14)  ·  Skin Diseases (14)

Interventions

Prednisone (35)  ·  bicalutamide (30)  ·  Goserelin (29)  ·  Radiotherapy (29)  ·  Leuprolide (25)  ·  Docetaxel (22)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (20)  ·  Flutamide (18)  ·  Triptorelin Pamoate (11)  ·  Zoledronic Acid (11)  ·  Gonadotropin-Releasing Hormone (10)  ·  gallium 68 PSMA-11 (10)  ·  Androgen Antagonists (9)  ·  Abiraterone Acetate (8)  ·  Mitoxantrone (7)

Sponsors

Radiation Therapy Oncology Group (18)  ·  Ferring Pharmaceuticals (17)  ·  Alliance for Clinical Trials in Oncology (11)  ·  AstraZeneca (7)  ·  Novartis Pharmaceuticals (7)  ·  SWOG Cancer Research Network (7)  ·  Sanofi (7)  ·  UNICANCER (7)  ·  European Organisation for Research and Treatment of Cancer - EORTC (6)  ·  Abbott (5)  ·  Amgen (5)  ·  National Cancer Institute (NCI) (5)  ·  Pfizer (5)  ·  Bayer (4)  ·  Blue Earth Diagnostics (4)

Countries

United States (162)  ·  Canada (93)  ·  France (72)  ·  United Kingdom (63)  ·  Netherlands (56)  ·  Germany (55)  ·  Belgium (53)  ·  Italy (51)  ·  Spain (51)  ·  Poland (43)  ·  Australia (41)  ·  Russia (41)  ·  Czechia (34)  ·  Sweden (33)  ·  Hungary (31)

Top investigators

Eric J. Small, MD (4)  ·  Michel Bolla, MD (4)  ·  Thomas Hope, MD (4)  ·  George Wilding, MD (3)

Results publications

PMID 34350976, PMID 24722180, PMID 29272162, PMID 38320143, PMID 25592642, PMID 36884035, PMID 22129214, PMID 33270906, PMID 35643841, PMID 35731340, PMID 36596347, PMID 21917607, PMID 23228299, PMID 24957547, PMID 25712310, PMID 25829400, PMID 26031410, PMID 26278649, PMID 26609008, PMID 29500065, PMID 30920593, PMID 31830211, PMID 32808077, PMID 33740734, PMID 33999161, PMID 34518652, PMID 35812443, PMID 37121865, PMID 37751207, PMID 42286315, PMID 10604271, PMID 10717606, PMID 10866876, PMID 10869758, PMID 11289126, PMID 11448906, PMID 11586207, PMID 11828353, PMID 12126818, PMID 12160582, PMID 12177096, PMID 12208577, PMID 12560440, PMID 12743142, PMID 12947070, PMID 14572748, PMID 14581419, PMID 14747052, PMID 15020604, PMID 15169799

NIH funding

2008 (7), U10CA031946 (5), 2009 (4), 2018 (4), U10CA032102 (3), 2016 (2), 2017 (2), U10CA037429 (2), 2005 (1), 2015 (1), 2019 (1), 2023 (1), P30CA006927 (1), P30CA008748 (1), P30CA014236 (1)